All of our findings suggested that CB1 antagonist treatment reduced obesity‐associated NASH progression via reversion of immune system dysregulation and elevation of MAPK signal phosphorylation and the inflammatory responses in the liver tissue. The gene discussed is CNR1; the disease is metabolic dysfunction-associated steatohepatitis.